Experimental cohort: metastatic TNBC clinical trial | ||||
No. patients | Average age (median, IQR) | |||
29 | 59 (61, 15) | |||
Treatment arm | 12-week response | No. patients | ||
Capecitabine | 14 | CR | 1 | |
PR | 5 | |||
SD | 2 | |||
Paclitaxel | 15 | CR | 2 | |
PD | 2 | |||
SD | 1 | |||
Subgroup | ||||
Chemotherapy-naïve | 5 | |||
>12 months since chemotherapy | 16 | |||
Comparator cohort: early-stage breast cancer | ||||
No. patients | Average age (median, IQR) | |||
29 | 53 (53, 16) | |||
Stage | No. patients | Neoadjuvant treatment | No. patients | |
HR−, HER2− | ||||
II | 7 | ddAC-T | 6 | |
III | 1 | AC-T | 1 | |
HR+, HER2− | ||||
II | 8 | ddAC-T | 4 | |
III | 2 | |||
HR+/−, HER2+ | ||||
I | 1 | ddAC-THP | 8 | |
II | 8 | ddAC-TH | 1 | |
III | 2 |
CR, complete response; ddAC, dose-dense anthracycline and cyclophosphamide; H, trastuzumab; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IQR, interquartile range; P, pertuzumab; PD, progressive disease; PR, partial response; SD, stable disease; T, paclitaxel; TNBC, triple-negative breast cancer.